Vivo Capital Fund VIII, L.P.'s Form 4 filing
Terns Pharmaceuticals, Inc. (TERN) · filed Sep 8, 2022
- Accession no.
- 0001213900-22-054888
- Filed
- Sep 8, 2022, 8:00 PM ET
- Trade date
- Sep 7, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $2.16M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Capital Fund VIII, L.P.CIK 0001618788 | 10% Owner |
| Vivo Capital VIII, LLCCIK 0001618789 | 10% Owner |
| Vivo Capital Surplus Fund VIII, L.P.CIK 0001628048 | 10% Owner |
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2022 | Common Stock | PPurchaseAcquired | +600,000 | $3.60 | +$2,160,000 | 3,581,592 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.